Professor Lietzan Presents Paper at Law and Biosciences Workshop

On May 6, Professor Erika Lietzan presented her most recent paper at Stanford Law School, as part of its Law and the Biosciences Workshop. Her paper, Access Before Evidence and the Price of FDA’s New Drug Authorities, explores the costs of error and delay associated with federal government approval of new drugs, as well as costs associated with other less-studied aspects of the new drug regulatory framework.

Research for this paper was supported in part by funding from Scalia Law School’s Center for Protection of Intellectual Property, and the University of Richmond Law Review will be publishing the paper this summer.

Professor Lietzan teaches a course on FDA regulation of Drugs and Devices, as well as the Intellectual Property Survey, and before she joined Mizzou Law in 2014 she practiced food and drug law for 18 years in Washington, DC.